{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Benzo[g]quinazolin", "EGFR", "HER2", "benzenesulfonamide"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "29098904", "DateCompleted": {"Year": "2017", "Month": "11", "Day": "08"}, "DateRevised": {"Year": "2018", "Month": "12", "Day": "02"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": ["10.1080/14756366.2017.1389922"], "Journal": {"ISSN": "1475-6374", "JournalIssue": {"Volume": "33", "Issue": "1", "PubDate": {"Year": "2018", "Month": "Dec"}}, "Title": "Journal of enzyme inhibition and medicinal chemistry", "ISOAbbreviation": "J Enzyme Inhib Med Chem"}, "ArticleTitle": "Benzo[g]quinazolin-based scaffold derivatives as dual EGFR/HER2 inhibitors.", "Pagination": {"StartPage": "67", "EndPage": "73", "MedlinePgn": "67-73"}, "Abstract": {"AbstractText": ["Targeting EGFR has proven to be beneficial in the treatment of several types of solid tumours. So, a series of novel 2-(4-oxo-3-(4-sulfamoylphenyl)-3,4-dihydrobenzo[g]quinazolin-2-ylthio)-N-substituted acetamide 5-19 were synthesised from the starting material 4-(2-mercapto-4-oxobenzo[g]quinazolin-3(4H)-yl) benzenesulfonamide 4, to be evaluated as dual EGFR/HER2 inhibitors. The target compounds 5-19, were screened for their cytotoxic activity against A549 lung cancer cell line. The percentage inhibition of EGFR enzyme was measured and compared with erlotinib as the reference drug. Compounds 6, 8, 10, and 16 showed excellent EGFR inhibitory activity and were further selected for screening as dual EGFR/HER2 inhibitors. The four selected compounds showed IC<sub>50</sub> ranging from 0.009 to 0.026\u2009\u00b5M for EGFR and 0.021 to 0.069\u2009\u00b5M for the HER2 enzyme. Compound 8 was found to be the most potent in this study with IC<sub>50</sub> 0.009 and 0.021\u2009\u00b5M for EGFR and HER2, respectively."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "a Department of Pharmacognosy, College of Pharmacy , King Saud University , Riyadh , Saudi Arabia."}, {"Identifier": [], "Affiliation": "b Department of Drug Radiation Research , National Center for Radiation Research and Technology, Egyptian Atomic Energy Authority , Cairo , Egypt."}], "LastName": "Ghorab", "ForeName": "Mostafa M", "Initials": "MM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "a Department of Pharmacognosy, College of Pharmacy , King Saud University , Riyadh , Saudi Arabia."}], "LastName": "Alsaid", "ForeName": "Mansour S", "Initials": "MS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "b Department of Drug Radiation Research , National Center for Radiation Research and Technology, Egyptian Atomic Energy Authority , Cairo , Egypt."}], "LastName": "Soliman", "ForeName": "Aiten M", "Initials": "AM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "c Medicinal, Aromatic and Poisonous Plants Research Center (MAPPRC), College of Pharmacy , King Saud University , Riyadh , Saudi Arabia."}], "LastName": "Al-Mishari", "ForeName": "Abdullah A", "Initials": "AA"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "J Enzyme Inhib Med Chem", "NlmUniqueID": "101150203", "ISSNLinking": "1475-6366"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Protein Kinase Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Quinazolines"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "ErbB Receptors"}], "MeshHeadingList": [{"QualifierName": ["chemical synthesis", "chemistry", "pharmacology"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Proliferation"}, {"QualifierName": [], "DescriptorName": "Dose-Response Relationship, Drug"}, {"QualifierName": [], "DescriptorName": "Drug Screening Assays, Antitumor"}, {"QualifierName": ["antagonists & inhibitors", "metabolism"], "DescriptorName": "ErbB Receptors"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Molecular Structure"}, {"QualifierName": ["chemical synthesis", "chemistry", "pharmacology"], "DescriptorName": "Protein Kinase Inhibitors"}, {"QualifierName": ["chemical synthesis", "chemistry", "pharmacology"], "DescriptorName": "Quinazolines"}, {"QualifierName": [], "DescriptorName": "Structure-Activity Relationship"}]}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Gschwind A, Fischer OM, Ullrich A.. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004;4:361\u201370.", "ArticleIdList": ["15122207"]}, {"Citation": "Tao X-X, Duan Y-T, Chen L-W, et al. . Design, synthesis and biological evaluation of pyrazolyl-nitroimidazole derivatives as potential EGFR/HER-2 kinase inhibitors. Bioorg Med Chem Lett 2016;26:677\u201383.", "ArticleIdList": ["26652482"]}, {"Citation": "Ajani OO, Obafemi CA, Nwinyi OC, Akinpelu DA.. Microwave assisted synthesis and antimicrobial activity of 2-quinoxalinone-3-hydrazone derivatives. Bioorg Med Chem 2010;18:214\u201321.", "ArticleIdList": ["19948407"]}, {"Citation": "Kennedy SP, Hastings JF, Han JZ, Croucher DR.. The under-appreciated promiscuity of the epidermal growth factor receptor family. Front Cell Dev Biol 2016;4:88\u201399.", "ArticleIdList": ["PMC4992703", "27597943"]}, {"Citation": "Reid A, Vidal L, Shaw H, de Bono J.. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 2007;43:481\u20139.", "ArticleIdList": ["17208435"]}, {"Citation": "Abdelgawad MA, Bakr RB, Alkhoja OA, Mohamed WR.. Design, synthesis and antitumor activity of novel pyrazolo [3, 4-d] pyrimidine derivatives as EGFR-TK inhibitors. Bioorg Chem 2016;66:88\u201396.", "ArticleIdList": ["27043178"]}, {"Citation": "Marshall C. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995;80:179\u201385.", "ArticleIdList": ["7834738"]}, {"Citation": "Hirsch F, Varella-Garcia M, Cappuzzo F.. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene 2009;28:S32\u20137.", "ArticleIdList": ["19680294"]}, {"Citation": "Ciardiello F, Tortora G.. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958\u201370.", "ArticleIdList": ["11595683"]}, {"Citation": "Johnston S, Leary A.. Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. Drugs Today 2006;42:441\u201353.", "ArticleIdList": ["16894399"]}, {"Citation": "Zhang C, Li W.. Regioselective synthesis of 6-aryl-benzo [h][1, 2, 4]-triazolo [5, 1-b] quinazoline-7, 8-diones as potent antitumoral agents. Bioorg Med Chem Lett 2013;23:5002\u20135.", "ArticleIdList": ["23871222"]}, {"Citation": "Elkamhawy A, Farag AK, Viswanath ANI, et al. . Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: design, synthesis, kinase assay, cell-based assay, and molecular docking. Bioorg Med Chem Lett 2015;25:5147\u201354.", "ArticleIdList": ["26475520"]}, {"Citation": "Tu Y, Wang C, Xu S, et al. . Design, synthesis, and docking studies of quinazoline analogues bearing aryl semicarbazone scaffolds as potent EGFR inhibitors. Bioorg Med Chem 2017;25:3148\u201357.", "ArticleIdList": ["28428040"]}, {"Citation": "Yin S, Tang C, Wang B, et al. . Design, synthesis and biological evaluation of novel EGFR/HER2 dual inhibitors bearing a oxazolo [4, 5-g] quinazolin-2 (1H)-one scaffold. Eur J Med Chem 2016;120:26\u201336.", "ArticleIdList": ["27187856"]}, {"Citation": "Pao W, Miller V, Zakowski M, et al. . EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306\u201311.", "ArticleIdList": ["PMC516528", "15329413"]}, {"Citation": "Schuler M, Yang J-H, Park K, et al. . Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Ann Oncol 2016;27:417\u201323.", "ArticleIdList": ["PMC4769992", "26646759"]}, {"Citation": "Lee CK, Brown C, Gralla RJ, et al. . Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 2013;105:595\u2013605.", "ArticleIdList": ["23594426"]}, {"Citation": "Wang C, Sun Y, Zhu X, et al. . Novel quinazoline derivatives bearing various 4\u2010aniline moieties as potent EGFR inhibitors with enhanced activity against NSCLC cell lines. Chem Biol Drug Des 2016;87:635\u201343.", "ArticleIdList": ["26613384"]}, {"Citation": "Hynes NE, Lane HA.. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341\u201354.", "ArticleIdList": ["15864276"]}, {"Citation": "Stamos J, Sliwkowski MX, Eigenbrot C.. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002;277:46265\u201372.", "ArticleIdList": ["12196540"]}, {"Citation": "Casini A, Scozzafava A, Mincione F, et al. . Carbonic anhydrase inhibitors: water-soluble 4-sulfamoylphenylthioureas as topical intraocular pressure-lowering agents with long-lasting effects. J Med Chem 2000;43:4884\u201392.", "ArticleIdList": ["11123998"]}]}], "History": [{"Year": "2017", "Month": "11", "Day": "4", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "11", "Day": "4", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "11", "Day": "9", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "11", "Day": "3"}], "PublicationStatus": "ppublish", "ArticleIdList": ["29098904", "PMC6010119", "10.1080/14756366.2017.1389922"]}}]}